Siga Technologies Inc (SIGA) |
|
Price: $7.3300
$0.42
6.078%
|
Day's High:
| $7.36
| Week Perf:
| 49.9 %
|
Day's Low: |
$ 6.84 |
30 Day Perf: |
46.31 % |
Volume (M): |
1,746 |
52 Wk High: |
$ 7.36 |
Volume (M$): |
$ 12,797 |
52 Wk Avg: |
$5.31 |
Open: |
$6.89 |
52 Wk Low: |
$4.22 |
|
|
Market Capitalization (Millions $) |
525 |
Shares
Outstanding (Millions) |
72 |
Employees |
60 |
Revenues (TTM) (Millions $) |
140 |
Net Income (TTM) (Millions $) |
68 |
Cash Flow (TTM) (Millions $) |
51 |
Capital Exp. (TTM) (Millions $) |
0 |
Siga Technologies Inc
Siga Technologies Inc. is a biotechnology company that specializes in the development and commercialization of pharmaceutical products for use in the defense, medical and research sectors. The company was founded in 1995 by Dr. Eric Rose, and is headquartered in New York, New York. Siga Technologies is publicly traded on the NASDAQ exchange under the ticker symbol SIGA.
The primary focus of Siga Technologies' research and development efforts is on the development of drugs that can be used to treat diseases caused by bioterrorism agents such as smallpox, Ebola, and anthrax. The company has developed a number of proprietary antiviral and antibiotic therapeutics that have undergone clinical trials and have been approved by the U.S. Food and Drug Administration (FDA). One such antiviral drug is TPOXX, which is used to treat smallpox infections and has been stockpiled by the U.S. Department of Health and Human Services.
Siga Technologies operates in two primary segments: government and commercial. The government segment focuses on developing and testing drugs for use in biodefense and public health preparedness, and includes contracts with agencies such as the Department of Defense, the National Institutes of Health, and the Biomedical Advanced Research and Development Authority. The commercial segment focuses on exploring the use of Siga's drugs in other areas, such as the treatment of chronic viral diseases like hepatitis B and C.
The company has a strong commitment to research and development, and has formed partnerships with other biotechnology companies, academic institutions, and government agencies to advance its drug development programs. Siga Technologies employs a team of experienced researchers, scientists, and clinical experts who are committed to advancing the company's mission of developing effective treatments for infectious diseases.
Overall, Siga Technologies is a leading biotechnology company that specializes in developing highly effective drugs for use in the defense, medical, and research sectors. With its strong commitment to research and development and its focus on innovative drug development programs, the company is well-positioned to continue its growth and success in the years ahead.
Company Address: 31 East 62nd Street New York 10065 NY
Company Phone Number: 672-9100 Stock Exchange / Ticker: NASDAQ SIGA
|
|
|
|
|
Stock Performances by Major Competitors |
|
|
Siga Technologies Inc
In the wake of Siga Technologies Inc's notable revenue advance of 925.528% year on year to $116.48 million in its fiscal timeframe ending December 31, 2023, there may be a cause for concern when examining the company's overall performance. While the company has turned a surplus by exhibiting EPS at $1.02, compared to a net loss per share of $-0.01 in the preceding quarter, and achieved earnings of $72.256 million in the same fiscal timeframe, the underlying financial indicators paint a different picture. Firstly, the company's financial performance seems to be heavily reliant on seasonal fluctuations. The inventories have declined to $64.2 million from the previous quarter, indicating a potential lack of demand for their products. Although this marks an increase relative to the same period last year, it is important to bear in mind the context of the seasonal nature of the business.
|
Management Changes
Published Mon, Jan 22 2024 12:30 PM UTC
SIGA Technologies, Inc. (SIGA), a prominent pharmaceutical company specializing in the health security market, has recently shared news of the appointment of Dr. Diem Nguyen as their new Chief Executive Officer (CEO). With expertise encompassing a Ph.D. and an MBA, Dr. Nguyen's arrival is anticipated to bring fresh perspective and drive growth for SIGA starting Jan...
|
Siga Technologies Inc
Siga Technologies Inc, a major player in the pharmaceutical preparations sector, recently reported its third-quarter earnings for 2023, and the results were disappointing. The company saw a sharp decline in revenue, which faded by a staggering -87.211% to $9.24 million. Additionally, its net loss per share increased to $-0.01, compared to the same period last year. Contrary to the rest of the sector, which witnessed a 1.86% improvement in top-line revenue relative to the previous year, Siga Technologies Inc struggled to maintain its financial standing. From the preceding reporting period, the company experienced a significant surge in revenue by 57.11%, from $5.88 million. However, this growth is overshadowed by the overall decline in revenue for the third quarter of 2023.
|
Siga Technologies Inc
Siga Technologies Inc, a major player in the pharmaceutical preparations industry, has seen a significant improvement in its stock performance, with a 14.48% increase in the preceding 30 days and a remarkable 22.79% growth over the past 12 months. However, these positive market indicators might seem surprising given the company's disastrous second-quarter results for 2023. This article aims to interpret the contrasting financial results and discuss their potential impact on Siga Technologies Inc going forward. Challenging Second Quarter: Siga Technologies' financial report for the second quarter of 2023 was anything but impressive. The company experienced a disheartening decline in revenue by -64.732% to $5.88 million compared to the same reporting period the previous year. Furthermore, the net deficit per share widened to $-0.04, indicating a deterioration from the previous year's similar reporting season. These figures present a gloomy picture of the company's financial health during this period.
|
Siga Technologies Inc
Investors in the stock market are always looking for companies that have strong fundamentals and steady returns. One such company that has caught the attention of many is Siga Technologies Inc. The company reported an impressive return on equity (ROE) of 20.68% for the first quarter of 2023, which is above their average return on equity. Although the ROE fell relative to the previous period, it was due to the decline in net income. Compared to other companies in the Major Pharmaceutical Preparations industry, Siga Technologies Inc was slightly left behind in terms of return on equity with only nine other companies surpassing them. However, the company's overall ranking has advanced in the quarter to 313, up from 791 in the previous quarter, indicating an improving financial performance.
|
Per Share |
Current |
Earnings (TTM) |
0.96 $ |
Revenues (TTM) |
1.95 $
|
Cash Flow (TTM) |
0.72 $ |
Cash |
2.1 $
|
Book Value |
2.75 $
|
Dividend (TTM) |
0.45 $ |
|
Per Share |
|
Earnings (TTM) |
0.96 $
|
Revenues (TTM) |
1.95 $ |
Cash Flow (TTM) |
0.72 $ |
Cash |
2.1 $
|
Book Value |
2.75 $ |
Dividend (TTM) |
0.45 $ |
|
|
|
|